Anaheim Clinical Trials

Recent papers from Anaheim Clinical Trials

1. Phase 1, open‐label, randomized study of the elecoglipron pharmacokinetic profile in healthy participants under fed and fasted conditionsBritish Journal of Clinical Pharmacology · 2026
2. Test–retest reliability of clinical accommodative measures in adolescentsOptometry and Vision Science · 2026
3. Pharmacokinetic Comparability of ABP 654, a Biosimilar to Ustekinumab, Administered Either via Prefilled Syringe or Autoinjector in Healthy Adults: Results from a Randomized, Open‐Label, Parallel‐Group StudyClinical Pharmacology in Drug Development · 2026
4. Suzetrigine, a Non-Opioid NaV1.8 Inhibitor With Broad Applicability for Moderate-to-Severe Acute Pain: A Phase 3 Single-Arm Study for Surgical or Non-Surgical Acute PainJournal of Pain Research · 2025
5. Non‐clinical and first‐in‐human characterization of ECC5004 / AZD5004 , a novel once‐daily, oral small‐molecule GLP ‐1 receptor agonistDiabetes Obesity and Metabolism · 2024
6. Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled studyDiabetes Obesity and Metabolism · 2024
7. An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-lifeHuman Vaccines & Immunotherapeutics · 2023
8. Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adultsnpj Vaccines · 2023
9. Celecoxib‐tramadol co‐crystal in patients with moderate‐to‐severe pain following bunionectomy with osteotomy: A phase 3, randomized, double‐blind, factorial, active‐ and placebo‐controlled trialPain Practice · 2022
10. A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal ImpairmentEuropean Journal of Drug Metabolism and Pharmacokinetics · 2022
11. Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairmentBritish Journal of Anaesthesia · 2021
12. Gluten Degradation, Pharmacokinetics, Safety, and Tolerability of TAK-062, an Engineered Enzyme to Treat Celiac DiseaseGastroenterology · 2021
13. Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation StudyClinical and Translational Science · 2020
14. Rifabutin-Containing Triple Therapy (RHB-105) for Eradication of Helicobacter pylori: Randomized ERADICATE Hp TrialAntibiotics · 2020
15. Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P1R Modulator, Are Not Affected by Ethnicity in Healthy Asian and White SubjectsClinical and Translational Science · 2020
16. Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trialHuman Vaccines & Immunotherapeutics · 2020
17. A two-part phase 1 study to establish and compare the safety and local tolerability of two nasal formulations of XF-73 for decolonisation of Staphylococcus aureus: A previously investigated 0.5 mg/g viscosified gel formulation versus a modified formulationJournal of Global Antimicrobial Resistance · 2019
18. Insulin Resistance and Serum Magnesium Concentrations among Women with Polycystic Ovary SyndromeCurrent Developments in Nutrition · 2019
19. HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in herniorrhaphy: results from the phase 3 EPOCH 2 studyHernia · 2019
20. Blunted Evoked Prouroguanylin Endocrine Secretion in Chronic ConstipationClinical and Translational Gastroenterology · 2019